United States-based Rigel Pharmaceuticals Inc (Nasdaq: RIGL) announced on Wednesday that it has completed its license agreement with United States-based Eli Lilly and Company.
This move is subsequent to the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976.
Both firms have signed a global exclusive license agreement and strategic collaboration to co-develop and commercialise Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. Based on the partnership, Eli Lilly will also head all clinical development of penetrating RIPK1 inhibitors in central nervous system diseases.
According to the terms of the contract, Rigel has received a USD125m upfront cash payment from Eli Lilly. Additional details about the collaboration can be found in Rigel's Form 8-K filed with the Securities and Exchange Commission on 18 February 2021.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial